Form 10 Explorer
10-K
Annual Report
60 DEGREES PHARMACEUTICALS, INC.

SXTPW

NASDAQ

CIK: 1946563

File #: 001-41719

Period End: Dec 31, 2023

Fiscal Year: 2023

View on EDGAR
Balance Sheet
51 line items · 2 periods
XBRL
ItemDec 31, 2023Dec 31, 2022
Current Assets:
Cash
2,142,485264,865
Accounts Receivable
231,33245,965
Prepaid and Other Assets
4,402,602200,967
Deferred Offering Costs
68,629
Inventory, net
466,169518,578
Total Current Assets
7,242,5881,099,004
Property and Equipment, net
57,76121,300
Other Assets:
Right of Use Asset
13,51712,647
Long-Term Prepaid Expense
242,647
Intangible Assets, net
227,258164,255
Total Other Assets
483,422176,902
Total Assets
7,783,7711,297,206
Current Liabilities:
Accounts Payable and Accrued Expenses
506,206758,668
Lease Liability
13,65013,000
Deferred Compensation
325,000
Related Party Notes, net (including accrued interest)
195,097
Debenture
4,276,609
SBA EIDL (including accrued interest)
8,7722,750
Promissory Notes (including accrued interest)
16,855,887
Knight
16,319,986
Bridge Notes
535,901
Derivative Liabilities
2,306,7961,129,840
Derivative Liabilities - Related Parties
364,360
Total Current Liabilities
2,835,42423,921,211
Long-Term Liabilities:
Deferred Compensation
255,000
SBA EIDL (including accrued interest)
150,251160,272
Promissory Notes (including accrued interest)
1,109,783
Note, Including Amendment
1,109,783
Total Long-Term Liabilities
150,2511,525,055
Total Liabilities
2,985,67525,446,266
SHAREHOLDERS’ EQUITY (DEFICIT)
Series A Preferred Stock, $0.0001 par value, 1,000,000 shares authorized; 78,803 and 0 issued and outstanding as of December 31, 2023 and December 31, 2022, respectively (Note 6)
9,858,040
Common Stock, $0.0001 par value, 150,000,000 shares authorized; 5,810,089 and 2,386,009 issued and outstanding as of December 31, 2023 and December 31, 2022, respectively (Note 6)
581239
Additional Paid-in Capital
27,456,8025,164,461
Accumulated Other Comprehensive Income
135,56173,708
Accumulated Deficit
(32,580,850)(28,815,148)
60P Shareholders’ Equity (Deficit):
4,870,134(23,576,740)
Noncontrolling Interest
(72,038)(572,320)
Total Shareholders’ Equity (Deficit)
4,798,096(24,149,060)
Series A Preferred Stock - Preferred Stock
9,858,040
Common Stock
581239
Additional Paid-In Capital
27,456,8025,164,461
Accumulated Deficit
(32,580,850)(28,815,148)
Accumulated Other Comprehensive Income (Loss)
135,56173,708
Total Shareholders’ Equity (Deficit) Attributable to 60P
4,870,134(23,576,740)
Noncontrolling Interest on Shareholders
(72,038)(572,320)
Total Liabilities and Shareholders’ Equity (Deficit)
7,783,7711,297,206